Effect of TGF-β1 and ATRA on HL-60 cell differentiation
| Treatment . | CD14+, % . | CD66b+, % . | NSE+, % . |
|---|---|---|---|
| Control | 4 ± 2 | 4 ± 1 | 1 ± 1 |
| TGF-β1 | 23 ± 3 | 3 ± 1 | 22 ± 5 |
| ATRA | 5 ± 2 | 90 ± 7 | 2 ± 1 |
| TGF-β1 + ATRA | 46 ± 4 | 45 ± 9 | 26 ± 4 |
| Treatment . | CD14+, % . | CD66b+, % . | NSE+, % . |
|---|---|---|---|
| Control | 4 ± 2 | 4 ± 1 | 1 ± 1 |
| TGF-β1 | 23 ± 3 | 3 ± 1 | 22 ± 5 |
| ATRA | 5 ± 2 | 90 ± 7 | 2 ± 1 |
| TGF-β1 + ATRA | 46 ± 4 | 45 ± 9 | 26 ± 4 |
Cells were treated with 10 ng/mL TGF-β, 100 nM ATRA, or both for 4 days. Antibodies and FACS analysis and assay for NSE are as described in “Materials and methods.”